Table 2.
Nordic treatment regimen for MCL
| MCL1: 1996–2000 [16] | MCL2: 2000–2006 [8, 9] | MCL3: 2005–2009 [29] | |
|---|---|---|---|
| No. | 41 | 160 | 160 |
| Median age (range), y | 56 (38–65) | 56 (32–65) | 58 (28–65) |
| MIPI score (%) Low/Int/High |
8/46/23/23a | 51/26/23 | 48/31/21 |
| Induction | Maxi-CHOP21a | R-Maxi-CHOP21 alternating with R-HD-Ara-c | R-Maxi-CHOP21 alternating with R-HD-Ara-c |
| Intensification therapy | BEAM/BEAC+ASCT | BEAM/BEAC+ASCT+/− rituximab | BEAM/BEAC+ (Zevalin, if<CR) + ASCT |
| ORR(%) | 96 | 96 | 97 |
| CR (%) | 89 | 54 | 82 |
| Follow-up (ys) | 2.8 | 11.4 | 4.4 |
| mPFS (ys) | 4-y FFS, 20% | 8.5 | NR (4-y PFS, 71%) |
| mOS (ys) | 4-y OS, 61% | 12.7 | NR (4-y OS, 78%) |
| TRM (%) | 2 | 7 | 6 |
| Second malignancy(%) | 7 | 6 | 4 |
Abbreviations as indicated in the Table 1
Note: FFS failure-free survival, a IPI Low/Low-Inter/Inter-High/High; BEAM/BEAC Carmustine, etoposide, cytarabine, and melphalan or the same regimen with cyclophosphamide instead of melphalan; Zevalin, 90Y-ibritumomab-tiuxetan